Verseon (LSE:VERS) NonCurrent Deferred Liabilities : £0.00 Mil (As of Jun. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Verseon NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Verseon's non-current deferred liabilities for the quarter that ended in Jun. 2019 was £0.00 Mil.

Verseon NonCurrent Deferred Liabilities Historical Data

The historical data trend for Verseon's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon NonCurrent Deferred Liabilities Chart

Verseon Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

Verseon Semi-Annual Data
	Dec11	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial									-	-	-	-	-

Verseon NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Verseon's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Verseon (LSE:VERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

47071 Bayside Parkway, Fremont, CA, USA, 94538

Website

http://www.verseon.com

Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.